Skip to main content


Freshfields advises on Nasdaq listing of 111, Inc., a leading integrated online and offline healthcare platform in China

Freshfields Bruckhaus Deringer (‘Freshfields’) has advised JP Morgan Securities LLC, Citigroup Global Markets Inc., China International Capital Corporation, as the joint book-running managers and representatives of the underwriters in the listing of American Depositary Shares (‘the shares’) of 111, Inc. on the Nasdaq. The total offer value is estimated to be approximately US$100m (before the exercise of the over-allotment option). Trading of the shares commenced on 12 September 2018.

111, Inc. provides hundreds of millions of consumers with better access to pharmaceutical products and medical services, directly through its online retail pharmacy and indirectly through its offline pharmacy network. It also provides online consultation and electronic prescription services to consumers in China through its internet hospital. It intends to use the proceeds of the transaction to invest in R&D, particularly developing technology solutions; for sales and marketing purposes; and for general corporate purposes.

The Freshfields team advising on the deal was led by partners Valerie Ford Jacob, Yan Chen and Michael Levitt. They were supported by partner and China Chairman Teresa Ko and partners David Ludwick, Richard Bird, Robert Scarborough and counsel Jeremy Barr.


Notes for editors

About Freshfields Bruckhaus Deringer

Freshfields Bruckhaus Deringer LLP is a global law firm with a long-standing track record of successfully supporting the world's leading national and multinational corporations, financial institutions and governments on ground-breaking and business-critical mandates. Our 2,800 plus lawyers deliver results worldwide through our own offices and alongside leading local firms.  Our commitment, local and multi-national expertise and business know-how means our clients rely on us when it matters most.